hat
Kapasite nan asetilsalisilik asid inhibite touf nan plakèt siyifikativman diminye risk pou yo atak kè oswa konjesyon serebral. Nan desizyon li pran an, Komisyon an konfime ke tretman adisyonèl ak Aspirin ® aktif asid acetylsalicylic asid (ASA) siyifikativman diminye risk pou pasyan ki soufri nan yon atak kè oswa konjesyon serebral.
eng
The ability of acetylsalicylic acid to inhibit clumping of platelets significantly reduces the risk of heart attack or stroke. In its decision, the Commission confirms that the additional treatment with the Aspirin ® active ingredient acetylsalicylic acid (ASA) significantly reduces the risk of patients suffering from a heart attack or stroke.